Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Rearrange Those Chemists | Main | Boehringer Ingelheim Closing Laval Site »

September 18, 2012

Going After the Big Cyclic Ones

Email This Entry

Posted by Derek

I wrote last year about macrocyclic compounds and their potential as drugs. Now BioCentury has a review of the companies working in this area, and there are more of them than I thought. Ensemble and Aileron are two that come to mind (if you count "stapled peptides" as macrocycles, and I think they should). But there are also Bicycle, Encycle, Lanthio, Oncodesign, Pepscan, PeptiDream, Polyphor, Protagonist, and Transzyme. These companies have a lot of different approaches. Many of them (but not all) are using cyclic peptides, but there are different ways of linking these, different sorts of amino acids you can use in them, and so on. And the non-peptidic approaches have an even wider variety. So I've no doubt that there's room in this area for all these companies - but I also have no doubt that not all these approaches are going to work equally well. And we're just barely getting to the outer fringes of sorting that out:

While much of the excitement over macrocycles is due to their potential to disrupt intracellular protein-protein interactions, every currently disclosed lead program in the space targets an extracellular protein. This reality reflects the challenge of developing a potent and cell-penetrant macrocyclic compound.

Tranzyme and Polyphor are the only companies with macrocyclic compounds in the clinic. Polyphor’s lead compound is POL6326, a conformationally constrained peptide that antagonizes CXC chemokine receptor 4 (CXCR4; NPY3R). It is in Phase II testing to treat multiple myeloma (MM) using autologous transplantation of hematopoietic stem cells.

Tranzyme’s lead compound is TZP-102, an orally administered ghrelin receptor agonist in Phase IIb testing to treat diabetic gastroparesis.

Two weeks ago, Aileron announced it hopes to start clinical development of its lead internally developed program in 2013. The compound, ALRN-5281, targets the growth hormone-releasing hormone (GHRH) receptor.

Early days, then. It's understandable that the first attempts in this area will come via extracellular-acting, iv-administered agents - those are the lowest bars to clear for a new technology. But if this area is going to live up to its potential, it'll have to go much further along than that. We're going to have to learn a lot more about cellular permeability, which is a very large side effect (a "positive externality", as the economists say) of pushing the frontiers back like this: you figure these things out because you have to.

Comments (9) + TrackBacks (0) | Category: Drug Development | Pharmacokinetics


COMMENTS

1. ronathan richardson on September 18, 2012 8:51 AM writes...

Not sure if the link was in there somewhere, but here it is:
http://www.biocentury.com/biotech-pharma-news/products/2012-09-17/maturing-macrocycle-chemistry-drives-explosion-of-biotech-newcos-biopharma-deals-a7

Permalink to Comment

2. JB on September 18, 2012 9:05 AM writes...

Broad too, although the library is not exclusively macrocycles- a range of ring sizes from 4 to 18, non-peptide-
PubMed IDs 22252910, 21875084, 21526820
One of the 14-member macrocycles is a malaria lead (PMID 22328964) so is likely getting into cells.
Also just announced a deal with AZ for screening against microbes.

Permalink to Comment

3. Nick Terrett on September 18, 2012 11:35 AM writes...

As CSO of one of the companies cited in the article (Ensemble Therapeutics), I should comment on cell penetration. We’ve been in the game of macrocycles for several years now and have now found many macrocycles that get into cells and are active against multiple intracellular targets. Our IL17 program, although an extracellular target, has generated compounds with oral bioavailability and efficacy in disease models.

So while there’s much still to be done in this space, our experience is that cellular penetration either as a prerequisite for oral bioavailability or as a necessity for hitting intracellular targets is fully attainable with macrocycles.

Permalink to Comment

4. Anonymous on September 18, 2012 3:27 PM writes...

Depends how you classify "macrocycle" I suppose. One could include two additional orally administered "macrocycles" that are currently under clinical development, both originating from S*Bio (Singapore). The first is SB-1513 (pacritinib), a JAK2/FLT3 inhibitor being developed to treat myeloproliferative disease. Pacritinib was acquired by "Cell Therapeutics" (Seattle, WA) earlier this year. The second is SB-1317 (TG02), also a JAK2/FLT3 inhibitor being developed to treat hematological disorders (licensed to Tragara Pharma, San Diego).

Permalink to Comment

5. AW on September 18, 2012 4:41 PM writes...

Just to let everybody know, an ACS medicinal chemistry symposium is being organized on exactly this topic for the fall meeting in Indianapolis 2013. Hope to see ya'll there.

Permalink to Comment

6. Anon on September 18, 2012 7:24 PM writes...

"Other naturally derived cyclic peptides include the antibiotics erythromycin and vancomycin, and the immunosuppressant tacrolimus."

Uhhh..Ahem...not exactly. I will give you vanco as a non-ribosomal peptidic product but erythro and FK-506 as macrocyclic peptides? 15 yards, loss of down.

Permalink to Comment

7. okemist on September 19, 2012 9:41 AM writes...

I know of a modified cyclosporin in the clinic as an oral anti-viral, but it has been over a year and I am not sure how far it has gotten.

Permalink to Comment

8. Anon on September 19, 2012 9:59 AM writes...

Any molecule that has the ability to adopt conformations that can hide its polarity has significantly higher chances of passively crossing membranes including, macrocycles. We should already start thinking about correcting for PSA and molecular polarity parameters for molecules that can adopt such conformations. More on this in our upcoming publication.

Permalink to Comment

9. As2O3 on September 21, 2012 9:33 PM writes...

Melanotan II would presumaby qualify as a macrocycle? That's already being injected by millions, as are a bunch of other unlicenced "research" peptides...

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Worst Seminar
Conference in Basel
Messed-Up Clinical Studies: A First-Hand Report
Pharma and Ebola
Lilly Steps In for AstraZeneca's Secretase Inhibitor
Update on Alnylam (And the Direction of Things to Come)
There Must Have Been Multiple Chances to Catch This
Weirdly, Tramadol Is Not a Natural Product After All